Home › NDC Lookup › RxCUI directory › RxCUI 2049677

Cobicistat 150 MG / darunavir 800 MG / emtricitabine 200 MG / tenofovir alafenamide 10 MG... — RxCUI 2049677

RxNorm drug concept · Semantic branded drug
RxCUI 2049677 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2049677
Official nameCobicistat 150 MG / darunavir 800 MG / emtricitabine 200 MG / tenofovir alafenamide 10 MG Oral Tablet [Symtuza]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asSymtuza (cobicistat 150 MG / as darunavir ethanolate 800 MG / emtricitabine 200 MG / as tenofovir alafenamide fumarate 10 MG ) Oral Tablet; Symtuza 800 MG / 150 MG / 200 MG / 10 MG Oral Tablet
FDA products mapped1
Package NDCs mapped2
Reported Medicaid activity (SDUD)54,928 prescriptions · 43 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Emtricitabine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Emtricitabine doesn't cure HIV, but it's an important part of keeping the virus under control. It works by blocking an enzyme HIV needs to make copies of itself. When it's used alo...
  • What exactly does emtricitabine do — does it cure HIV?
  • Please don't stop without talking to your doctor first. If you also have hepatitis B, stopping emtricitabine can trigger a sudden, severe flare of hepatitis B — sometimes serious e...
  • Can I stop taking emtricitabine if I feel fine or if I also have hepatitis B?
📖 Read our full Emtricitabine guide →

🕸️ Concept Web — How Cobicistat 150 MG / darunavir 800 MG / emtricita... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Cobicistat 150 MG / darunavir 800 MG / emtricitabine 200 MG / tenofovir alafenamide 10 MG Oral Tablet [Symtuza] RxCUI 2049677

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 5

    The active substance itself — no strength, form, or brand attached yet.

    • Cobicistat 1306284
    • Darunavir 460132
    • Emtricitabine 276237
    • Tenofovir alafenamide 1721603
    • Cobicistat / darunavir / emtricitabine / tenofovir alafenamide 1996260
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Symtuza 2049672
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Cobicistat / darunavir / emtricitabine / tenofovir alafenamide Oral Tablet 2049670
    • Cobicistat / darunavir / emtricitabine / tenofovir alafenamide Oral Product 2049668
    • Cobicistat / darunavir / emtricitabine / tenofovir alafenamide Pill 2049669
    • Cobicistat / darunavir / emtricitabine / tenofovir alafenamide Oral Tablet [Symtuza] 2049674
    • Symtuza Oral Product 2049675
    • Symtuza Pill 2049676
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 6

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 20 of 21 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Cobicistat 150 MG / darunavir 800 MG / emtricitabine 200 MG / tenofovir alafenamide 10 MG Oral Tablet SCD · 2049671
  • Cobicistat 150 MG SCDC · 1306285
  • Darunavir 800 MG SCDC · 1359268
  • Emtricitabine 200 MG SCDC · 406016
  • Tenofovir alafenamide 10 MG SCDC · 1721608
  • Cobicistat / darunavir / emtricitabine / tenofovir alafenamide Oral Tablet SCDF · 2049670
  • Cobicistat / darunavir / emtricitabine / tenofovir alafenamide Oral Product SCDG · 2049668
  • Cobicistat / darunavir / emtricitabine / tenofovir alafenamide Pill SCDG · 2049669

Brand-Name Concepts

  • Cobicistat 150 MG / darunavir 800 MG / emtricitabine 200 MG / tenofovir alafenamide 10 MG [Symtuza] SBDC · 2049673
  • Cobicistat / darunavir / emtricitabine / tenofovir alafenamide Oral Tablet [Symtuza] SBDF · 2049674
  • Symtuza Oral Product SBDG · 2049675
  • Symtuza Pill SBDG · 2049676
  • Symtuza BN · 2049672

📦 FDA Products & Package NDCs

1 product · 2 package NDCs
2 package NDCs map to RxCUI 2049677 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
59676-0800-30 30 TABLET, FILM COATED in 1 BOTTLE (59676-800-30) Symtuza Janssen Products LP 2018-07-17
59676-0800-99 30 TABLET, FILM COATED in 1 BOTTLE (59676-800-99) Symtuza Janssen Products LP 2018-07-17
Observed labelers: Janssen Products LP (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$152.9630
Range $152.9630–$152.9630 · middle 50% $152.9630–$152.9630 · 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.